Abstract
No public abstract is available from the verified source records.
Hideaki Suzuki
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Non-invasive hemodynamic and echocardiographic changes following vericiguat initiation in heart failure with reduced ejection fraction: a prospective registry study
2000
Evaluating haemodynamic changes: vericiguat in patients with heart failure with reduced ejection fraction
10.1002/ehf2.14802 · 2024
Vericiguat: VICTORy or defeat?
10.1016/j.jchf.2025.102763 · 2026
Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
10.1002/ehf2.14050 · 2022
Age, sex, and outcomes in heart failure with reduced EF: insights from the VICTORIA trial
10.1016/j.jchf.2023.06.020 · 2023
Armstrong PW; for the VICTORIA Study Group. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial
10.1002/ejhf.2221 · 2021
Ejection fraction, biomarkers, and outcomes and impact of vericiguat on outcomes across EF in VICTORIA
10.1016/j.jchf.2022.12.014 · 2023
Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial
10.1001/jamacardio.2020.6455 · 2021
Assessment of biomarkers of myocardial injury, inflammation, and renal function in heart failure with reduced ejection fraction: The VICTORIA biomarker substudy
10.1016/j.cardfail.2022.12.013 · 2023
Assessing benefit in patients with heart failure and reduced ejection fraction: analysis of the VICTORIA trial using novel prognostic risk stratification
2025
No additional external references are available.